• Meng-Yan Wang, Jin-Chao Jia, Cheng-De Yang, and Qiong-Yi Hu.
• Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
• Chin. Med. J. 2019 Dec 5; 132 (23): 285628642856-2864.

ObjectiveAdult-onset Still's disease (AOSD) is a rare but clinically well-known polygenic systemic autoinflammatory disease. In this review, we aim to present frontiers in the pathogenesis, clinical features, diagnosis, biomarkers, disease course, prognosis, and treatment in AOSD.Data SourcesWe retrieved information from the PubMed database up to July 2019, using various search terms and relevant words, including AOSD and Still's disease.Study SelectionWe included data from peer-reviewed journals. Both basic and clinical studies were selected.ResultsPathogenesis of AOSD involves genetic background, infectious triggers, and immunopathogenesis, mainly the activation of macrophages and neutrophils followed by a cytokine storm. Diagnosis and prognosis evaluation of AOSD is still challenging; therefore, there is an urgent need to identify better biomarkers. Biologic agents, including interleukin (IL)-1β, IL-6, and tumor necrosis factor-α antagonists in the treatment of AOSD, have good prospect.ConclusionThis review highlights the advances in pathogenesis, potential biomarkers, disease course, and treatment in AOSD.

14 keywords...

hide…